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Abstract
Background
Adequate testing is critically important for control of the SARS-CoV-2 pandemic. Antibody
testing is an option for case management and epidemiologic studies, with high specificity
and variable sensitivity. However, characteristics of local populations may affect perfor-
mance of these tests. For this reason, the National Institute of Health (INS) and regulatory
agencies in Colombia require verification of diagnostic accuracy of tests introduced to the
Colombian market.
Methods
We conducted a validation study of the Abbott SARS-CoV-2 test for qualitative detection of
IgG using the Abbott Architect i2000SR. Participants and retrospective samples were
included from patients with suspected SARS-CoV-2 infection, age�18 years, and�8 days
elapsed since initiation of symptoms. Pre-pandemic plasma samples (taken before October
2019) were used as controls. We estimated the sensitivity, specificity and agreement
(kappa) of the Abbott IgG test compared to the gold standard (RT-PCR).
Results
The overall sensitivity was 83.1% (95% CI: 75.4–100). Sensitivity among patients with�14
days since the start of symptoms was 85.7%, reaching 88% in samples collected from
patients with COVID-19 symptoms onset >60 days. Specificity was 100% and the kappa
index of agreement was 0.804 (95% CI: 0.642–0.965).
Conclusions
Our findings show high sensitivity and specificity of the Abbott IgG test in a Colombian popu-
lation, which meet the criteria set by the Colombian INS to aid in the diagnosis of COVID-19.
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Data from our patient groups also suggest that IgG response is detectable in a high propor-
tion of individuals (88.1%) during the first two months following onset of symptoms.
Introduction
Three highly pathogenic human coronaviruses have been identified to date, the Middle East
respiratory syndrome coronavirus (MERS-CoV), the severe acute respiratory syndrome coro-
navirus (SARS-CoV) and the 2019 novel coronavirus (SARS-CoV-2). The coronavirus disease
2019 (COVID-19), caused by the infection with SARS-CoV-2 has caused millions of con-
firmed infections, resulting in more than 2.9 million fatalities worldwide [1]. The World
Health Organization (WHO) has highlighted adequate testing as critically important for con-
trol of the pandemic [2]. Reverse transcription polymerase chain reaction (RT-PCR) is the cur-
rent gold standard for the detection of SARS-CoV-2 [3] but has limitations related to cost and
infrastructure, and its sensitivity changes with the duration of symptoms.
Serological tests play a decisive role in prevention, epidemiological surveillance and patient
follow-up, especially for emerging infectious diseases [4, 5]. Antibody assay utility may be
enhanced with strategies such as testing acute vs convalescent sera [6], or through orthogonal
approaches [7–9]. The Cochrane Library published in June 2020 a review on the usefulness of
antibody tests for identification of current and past SARS-CoV-2 infections [10]. Having ana-
lyzed 54 studies that used different antibody detection platforms, both commercial and in-
house methods, the overall results showed a time-dependent increase in the sensitivity of anti-
body-based tests during active symptomatic infection, ranging from less than 30.1% in the first
week for the pooled results of IgG, IgM, IgA total antibodies and IgG/IgM, to a pooled sensitiv-
ity of 91.4% (95% CI 87.0 to 94.4) during the third week of infection (days 15 to 21) for the
combination of IgM/IgG.
In Colombia, dozens of different diagnostic tests based on the detection of IgM and / or
IgG entered the market, prompting the development of minimal performance requirements
by the Colombian National Institutes of Health (INS, Instituto Nacional de Salud) [11]. These
consider that sensitivity and specificity may vary depending on factors such as the epidemio-
logical and clinical settings, assay design and the viral genetics of SARS-CoV-2.
The Abbott SARS-CoV-2 test for qualitative detection of IgG on the Abbott Architect
i2000SR system (hereafter referred as Abbott IgG test), is a chemiluminescent microparticle
immunoassay that uses recombinant nucleocapsid protein for detection of anti-SARS-CoV-2
IgG antibodies in serum and plasma samples of patients with signs and symptoms of SARS--
CoV-2 infection [12, 13]. According to its package insert, the intended use is as a diagnostic
aid in detecting individuals with adaptive immunity against the virus, and claimed sensitivity
of 100% and specificity of> 90% [12, 13]. Performance reports in different countries and com-
munities, using the initial manufacturer recommended cutoff of 1.4, have consistently docu-
mented specificities >99%, and a range of sensitivities depending on the study population.
Among some of these studies, sensitivity has been reported to be 68% in mild/moderate com-
munity managed cases in the United Kingdom [14], and 93.5% in UK patients with samples
collected� 14 days post symptoms onset [15]. Two independent studies in populations in the
United States (US) reported 90.3% and 93.6% sensitivity in patients with symptoms onset
between 15–21 days [16, 17], while 100% sensitivity was reported in a US cohort of RT-PCR
positive patients, predominantly hospitalized, with samples obtained�17 days after onset of
symptoms and�13 days after RT-PCR positivity [18].
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In order to provide critical information for the use of serological tests in Colombia, we eval-
uated the performance, in terms of sensitivity and specificity, of the Abbott IgG test to aid in
the diagnosis of COVID-19 in patients who consult at the Fundación Valle del Lili (FVL) Uni-
versity Hospital in Cali, Colombia. Our primary aim was to determine whether the Abbott IgG
test achieved the goals of sensitivity�85% and specificity�90% for detection of SARS-CoV-2
infection, with reference to the gold standard of RT-PCR, as mandatory performance parame-
ters defined by the Colombian INS. In addition, we sought to estimate the concordance
between the performance of the Abbott IgG test and the gold standard of RT-PCR.
Materials and methods
Ethics statement
This research was approved and monitored by the Institutional Ethical Review Board (IRB) of
Fundación Valle del Lili -FVL- (approval number: 286–2020) and Centro Internacional de
Entrenamiento e Investigaciones Médicas -CIDEIM- (Approval number: 10–2020). Written
informed consent was obtained from all prospectively recruited participants or their legal rep-
resentatives, when unable to consent due to clinical reasons (e.g., ICU hospitalization). A
waiver of consent for retrospective stored samples was approved by the IRBs. Medical deci-
sions were not affected by participation in this study.
Study design and population
We conducted a diagnostic secondary validation (verification) [11] study with prospective and
retrospective participants. The prospective enrolment of participants was carried out at FVL,
and retrospective (stored samples) were selected at CIDEIM and FVL in Cali, Colombia.
Reporting of the study follows the Standard for the Reporting of Diagnostic Accuracy Studies
(STARD 2015) guidelines (S1 Table) [19]. Two groups of participants were planned for enrol-
ment in this study:
Group 1 (patients with suspected SARS-CoV-2 infection): inpatients and outpatients�18
years of age seeking healthcare in FVL, with suspected COVID-19 and�8 days after symptom
onset, were invited to participate in the study (prospective participants). In addition, stored
serum samples from patients with RT-PCR confirmed infection with SARS-CoV-2 were
selected for inclusion in the study if relevant clinical information was available (retrospective
participants). Exclusion criteria included immunosuppression (including HIV infection),
autoimmune diseases and immunosuppressant drug treatment.
Group 2 (pre-pandemic controls): plasma samples obtained from EDTA anti-coagulated
peripheral blood from patients consulting during January 2015 –September 2019, for unre-
lated pathologies (cutaneous ulcers), were selected from the biological specimen collection of
CIDEIM. These corresponded to samples from patients�18 years of age, with diagnosis of
cutaneous leishmaniasis (CL) and a negative HIV test.
Clinical samples: nasopharyngeal (NP) aspirate samples were obtained from all patients
with suspected SARS-CoV-2 infection (i.e. Group 1), using 3mL sterile saline buffer. One 15
mL sample of venous blood was collected from each study participant with onset of symptoms
�14 days. All serum samples were kept refrigerated until analysis (time to assay ranged
between 1 and 6 hours after sample procurement).
Index test: Abbott SARS-CoV-2 IgG test
This immunoassay is based on detection of IgG antibodies in plasma and serum samples,
which bind to SARS-CoV-2 recombinant antigen coated microparticles, via a
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chemiluminescent reaction measured by relative light units (RLU). The presence of SARS--
CoV-2 IgG antibodies is determined by comparing the RLUs in the reaction containing the
evaluated sample vs. the RLUs in the calibration control. The signal/cut off index (S/C) used
for this study was 1.4 as recommended by the manufacturer (<1.4 negative, and�1.4 positive
for anti-SARS-CoV-2 antibodies). Assay performance metrics met or exceeded manufacturer
specifications as per product insert.
Reference standard: SARS-CoV-2 RT-PCR
The RT-PCR assays were performed according to routine procedures at the FVL clinical labo-
ratory. The SARS CoV-2 RT-PCR assays Allplex™ SARS-CoV-2 (Seegene, run on Bio-Rad
CFX96 platform), AccuPower1 SARS-CoV-2 Real-Time RT-PCR (Bioneer, run on Bioneer
ExyStation™ 16 platform), GeneFinder™ COVID-19 Plus RealAmp (OSANG Healthcare, run
on ELITe InGenius™ platform), BD SARS-CoV-2 (Becton, Dickinson, run on BD MAX™ plat-
form), or VIASURE SARS-CoV-2 Real Time PCR™ (CerTest Biotec, run on QIAGEN Rotor-
Gene-Q platform), were performed as reference standards. All RT-PCR assays complied with
INS and FVL laboratory performance criteria. Only samples with a signal above the threshold
in the relevant RT-PCR viral gene target regions for each assay were considered positive, as per
the manufacturer instructions and internal standardized operating procedures (SOPs) at FVL.
All assays and reagents were stored and handled following manufacturers’ instructions. All
operators performed the assays following the internal SOPs of FVL. Staff performing the index
test were blinded to the results of RT-PCR while staff performing the reference standard were
blinded to results of the index test.
Clinical and laboratory data collection
Clinical and demographic data, including time since start of symptoms, disease severity and
outcomes, history of autoimmune diseases and immunosuppression, were collected from the
clinical records of patients or at the time of enrollment using a questionnaire. Laboratory
results were entered into a case report form, sourced from the original laboratory information
system records by a research assistant. All data were captured in a dedicated database utilizing
Research Electronic Data Capture (REDCapTM, www.project-redcap.org), hosted at the FVL
data center.
Sample size
Based on the Colombian INS guidelines for performance verification studies for SARS-CoV-2
diagnostic tests [20, 21], a minimum of 16 symptomatic RT-PCR positive patient samples are
required to meet regulatory criteria, considering goals of sensitivity�85% and specificity
�90% for detection of SARS-CoV-2 infection, with reference to the gold standard of RT-PCR.
For the power calculation, we used parameter values from the test insert [13]: 100% for sensi-
tivity and 99.6% for specificity. We also assumed that study participants would be recruited
prospectively from a group in which 9% would be symptomatic and RT-PCR positive. This
group needed to number 178 in order to achieve the required sample size for sensitivity (9% of
178 is 16).
Time constraints imposed by the unfolding pandemic required this recruitment plan to be
changed, and assessment of specificity was expedited by using a set of 61 banked pre-pandemic
plasma samples as described above. Simulation of 100,000 repeated samples of this sample
size, with 99.6% specificity, showed a power of 99.8% to establish specificity more than the
90% threshold, using the statistical methods described in the following section.
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Statistical analysis
For the primary objective, one-sided 95% confidence intervals are presented (since the hypoth-
eses about sensitivity and specificity were one-sided,�85% y�90%, respectively), as well as
two-sided 90% confidence intervals, using Wilson’s method [22]. This analysis was repeated
for subgroups defined in terms of time since the onset of symptoms. To determine agreement
between the index test and the reference standard, as well as the crude agreement (proportion
of cases in which the tests agree), the kappa index was calculated, the latter being a chance-
adjusted measure of agreement [23]. Landis & Koch’s descriptors for values of kappa were
used [24]. Predictive values were calculated as functions of sensitivity, specificity and preva-
lence by standard identities [25]. Patients with invalid results or missing data on results of ref-
erence or index tests were excluded from analysis. Analysis was done using the R software,
version 3.6.3.
Results
Between September 17th and October 9th, 2020, participants with presumed SARS-CoV-2
infections were invited to participate in this study. Overall, 260 potentially eligible retrospec-
tive participants were identified, of whom 48 had stored and available serum or plasma sam-
ples for IgG testing. In addition, 87 patients with RT-PCR confirmed SARS-CoV-2 infection
were eligible to participate by donating a blood sample; among them, 49 were included in the
study. Reasons for exclusion are detailed in Fig 1. No adverse events from performing the
index test or the reference standard were reported by the specimen donors.
Most of the Group 1 participants (prospectively or retrospectively recruited patients with
symptoms of COVID-19) were male (60.2%), with a mean age of 51.5 years (SD = 16.0). Fever,
cough and difficulty in breathing were the most common symptoms (Table 1). Time from the
initial symptoms until serologic testing was� 14 days for 92.8% of participants, and> 60 days
for 50.6% of participants. Median time between symptom initiation and respiratory specimen
sampling for molecular testing was 7 days. Regarding the clinical presentation, most of the
patients were classified as uncomplicated COVID-19 cases (35/83, 42.1%), followed by patients
with severe disease (36.1%). Uncomplicated cases were defined as patients who did not consult
the emergency room and were managed on an outpatient basis. Mild disease severity was con-
sidered as those patients that were hospitalized and did not require intensive care, and severe
cases corresponded to patients who required intensive care. Four patients (4/83; 4.8%) had a
fatal outcome.
For the pre-pandemic group, 61 eligible plasma samples from adult patients diagnosed with
cutaneous leishmaniasis were identified in the biological collection of CIDEIM; of these, 59
met the quality standards for inclusion in the study. Most plasma samples (75%) were obtained
from male participants with average age of 38 years (Fig 1).
Sensitivity, specificity and agreement
The sensitivity of the index test (in Group 1), relative to RT-PCR, is shown in Table 2: overall
it was 83.1%. The pre-specified subgroups, in terms of time elapsed since symptom onset, were
8–13 days and�14 days. A majority (93%) were in the latter category, and among these the
sensitivity was 85.7%. Of samples collected from patients with onset of COVID-19 symptoms
>60 days, 88% tested positive by the index test (Table 2), indicating that IgG responses can be
tracked in a high proportion of individuals during the first two months following onset of
symptoms.
The specificity of the test (in Group 2) was 100%, with all 59 samples testing negative on the
index test. This means that the point estimate of the positive predictive value (PPV) is 100%.
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Fig 1. Schematic representation of the study design and conduct. Flow diagram of the performance verification study. Shown are all eligible and
recruited patients and samples, as well as reasons for exclusion of participants during the study. Group 1: SARS-CoV-2 infected patients and samples.
Group 2: Pre-pandemic samples.
https://doi.org/10.1371/journal.pone.0256566.g001
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Fig 2 shows values of the negative predictive value (NPV), based on the point estimates of sen-
sitivity and specificity from the current study, and various values of prevalence (i.e. positivity
by RT-PCR). For a prevalence up to 33.3%, the NPV is over 90%.
As shown in Table 3, the kappa index of agreement was 0.804 (95% CI 0.642–0.965), which
is in the range considered by Landis & Koch as “almost perfect” [24]. The crude agreement
Table 1. Clinical and demographic characteristics of the study population.
Characteristic Group 1 Total
Included retrospectively Included prospectively
n = 34 n = 49 n = 83
Age (years): mean (SD) 54.6 (17.2) 49.4 (15.0) 51.5 (16.0)
Female sex: n (%) 13 (38.2) 20 (40.8) 33 (39.8)
Time since onset of symptoms
Median (range) 18 (10–58) 85 (10–142) 66 (10–142)
8–13 days: n (%) 5 (14.7) 1 (2.0) 6 (7.2)
�14 days: n (%) 29 (85.3) 48 (98.0) 77 (92.8)
>60 days (subset of previous row): n (% of total) 0 (0) 42 (85.7) 42 (50.6)
Disease severity: n (%)
Uncomplicated 12 (35.3) 23 (46.9) 35 (42.2)
Mild 5 (14.7) 13 (26.5) 18 (21.7)
Severe 17 (50) 13 (26.5) 30 (36.1)
Fatal outcome: n (%) 4 (11.8) 0 (0) 4 (4.8)
Family history of autoimmune disease
No - 35 (71.4) 35 (42.2)
Yes - 8 (16.3) 8 (9.6)
Missing 34 (100) 6 (12.2) 40 (48.2)
Symptoms
Fever: n (%) 25 (73.5) 26 (53.1) 51 (61.4)
Expectoration: n (%) 8 (23.5) 3 (6.1) 11 (13.3)
Asthenia o adynamia: n (%) 19 (55.9) 24 (49) 43 (51.8)
Cough: n (%) 27 (79.4) 31 (63.3) 58 (69.9)
Dyspnea: n (%) 22 (64.7) 19 (38.8) 41 (49.4)
Anosmia: n (%) 3 (8.8) 8 (16.3) 11 (13.3)
Myalgia: n (%) 8 (23.5) 19 (38.8) 27 (32.5)
Arthralgia: n (%) 8 (23.5) 14 (28.6) 22 (26.5)
Headache: n (%) 4 (11.8) 17 (34.7) 21 (25.3)
Odynophagia: n (%) 6 (17.6) 20 (40.8) 26 (31.3)
Gastrointestinal: n (%) 6 (17.6) 7 (14.3) 13 (15.7)
https://doi.org/10.1371/journal.pone.0256566.t001
Table 2. Performance analysis.
Index test result (Abbott IgG)





Total 69 (83.1) (75.4–100) (75.4–88.8) 14 (16.9) 83
Onset of symptoms to sampling interval
8–13 days 3 (50.0) (22.1–100) (22.1–77.9) 3 (50.0) 6
�14 days 66 (85.7) (77.9–100) (77.9–91.1) 11 (14.3) 77
>60 days (subset of previous
row)
37 (88.1) (77.5–100) (77.5–94.1) 5 (11.9) 42
https://doi.org/10.1371/journal.pone.0256566.t002
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(percentage of results in agreement) was 90.1%. Among the 14 RT-PCR positive/IgG negative
patients (Table 2), in three cases serum samples were obtained between 8–13 days after symp-
tom onset.
Post-hoc analyses: Exploring potential contributors to discrepancies
between tests
As of October 2020, Abbott released technical information for implementation of a “grey
zone” S/C index threshold (�0.49 and<1.4) in defining positive samples [26]. Applying this
alternative threshold to the RT-PCR positive/IgG negative samples, 7 of 14 samples would be
re-classified as IgG positive, while three of the 59 pre-pandemic samples would be re-classified
as positive (with S/C indices of 0.50, 0.54 and 0.65).
The identity of the gene target for SARS-CoV-2 detection by RT-PCR was available for 80
of the 83 RT-PCR positive patients. Amplification of the envelope protein (E) and RNA-
Fig 2. Negative predictive value (NPV) of the Abbott IgG test. NPVs were defined for the values of sensitivity and
specificity in Table 2 (83 and 100% respectively), as a function of prevalence as determined by RT-PCR [25].
https://doi.org/10.1371/journal.pone.0256566.g002
Table 3. Concordance analysis.
Index test result (Abbott IgG)
Positive: n Negative: n Total: n (%)
PCR positive (Group 1) 69 14 83 (58.5)
PCR negative (Group 2) 0 59 59 (41.5)
Total: n (%) 69 (48.6) 73 (51.4) 142
Index test result (Abbott IgG): subgroup analysis
PCR positive (Group 1, interval since symptoms onset�60 days) 37 5 42 (41.6)
PCR negative (Group 2) 0 59 59 (58.4)
Total: n (%) 37 (36.6) 64 (63.4) 101
https://doi.org/10.1371/journal.pone.0256566.t003
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dependent RNA polymerase (RdRp) genes was conducted in samples from 68 patients, while
E, RdRp and nucleocapsid protein (N) genes were amplified in 7, N in 4 and ORF1ab in one
sample. Ten of the 14 RT-PCR positive/IgG negative patients were diagnosed by amplification
of E and RdRP targets. Ct values for at least one PCR target amplification product were avail-
able for 77 samples, and of these, 65 were processed with the AccuPower1 SARS-CoV-2 Real-
Time RT-PCR on a Bioneer ExyStation 16 platform. No correlation between Ct values and
IgG test results were found with either E or RdRp targets.
We also explored possible relationships between Ct values, IgG S/C index and surrogates of
disease severity (C-reactive protein -CRP-, D-dimer, lactate dehydrogenase -LDH-, ferritin,
and interleukin 6 -IL6-), as possible contributors to the discrepant RT-PCR and Abbott IgG
tests results, but no correlations were found. Sample quality was excluded as a possible contrib-
utor to discrepant RT-PCR and IgG results, since positive and significant correlations were
found between different parameters of disease severity [27], within our patient cohort (Fig 3):
CRP levels were positively and significantly correlated to the neutrophil/lymphocyte index
(NLI), LDH and D-dimer (p<0.00001, Spearman ρ = 0.556, 0.703, 0.538, respectively), while
ferritin levels were positively and significantly correlated to LDH and IL6 (p<0.01, Spearman
ρ = 0.622, 0.536, respectively).
Discussion
With the increasing availability of anti-SARS-CoV-2 vaccines and the growing implementa-
tion of national vaccination strategies, quantitative and qualitative detection of anti-
Fig 3. Correlation of laboratory parameters of disease severity. Data from laboratory tests was obtained from the clinical records of study participants. Shown are the
graphical representation of the correlation analyses, as well as the parameters of significance and strength of the correlation for each data pair. C-RP (C-Reactive
Protein), NLI (Neutrophil/Lymphocyte index), LDH (lactate dehydrogenase), D-Dimer (fibrin degradation product), IL6 (Interleukin 6).
https://doi.org/10.1371/journal.pone.0256566.g003
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SARS-CoV-2 antibodies has re-emerged as a central tool for epidemiological surveillance, in
addition to supporting the diagnosis of infection. Here, we have verified the performance of
the Abbott IgG test to aid in diagnosis of COVID-19 in adult patients consulting FVL, a high-
level referral university hospital in Cali, Colombia. Our data show high sensitivity and specific-
ity parameters when compared to the standard RT-PCR, indicating that Abbott IgG test meets
the criteria set by the Colombian INS to aid in the diagnosis of COVID-19. It also meets the
WHO criteria for specificity (�97%) in tests aimed to detect prior SARS-CoV-2 infection [28].
Agreement with the molecular test was very good (kappa 0.804, 95% CI: 0.642–0.965), and the
estimated sensitivity of the test remained above the threshold of�85% (as established by the
Colombian guidelines for antibody testing), two months after infection, supporting its use in
this population.
These results are similar to those reported in another study conducted by the Colombian
INS, which showed sensitivity of 85.2% of the Abbott IgG test in RT-PCR positive symptom-
atic patients (n = 260), increasing to 97.2% in those patients with history of hospitalization due
to COVID (n = 147) [20]. This study followed the protocol for secondary validation of the INS
[11, 29], which sets a standard for the evaluation of diagnostic technologies for SARS-CoV-2
in the country and contributes to comparability of evaluations of tests across laboratories. Dis-
ease severity is a known factor related to the ability of current tests to detect antibody against
SARS-CoV-2 [30]; in our study, most of the cases were mild and only 36% had severe disease,
which may partly explain the estimated sensitivity in this study.
Another factor influencing the agreement between RT-PCR and serological tests is the time
of sampling for each of the tests: samples obtained during the first 5–10 days after onset of
symptoms are better suited for RT-PCR-based diagnosis as viral loads will likely be near their
peak, while informative serum samples for IgG detection are best obtained after 14 days fol-
lowing onset of symptoms, in accordance with the time required for mounting an antibody
response to SARS-CoV-2 infection [3, 31, 32]. In our cohort, among the 14 patients with
RT-PCR positive/IgG negative results, only 3 corresponded to samples obtained between 8–13
days after onset of symptoms. Thus, other factors beyond time-to-sampling may contribute to
this difference.
Based on the point estimates of sensitivity and specificity from our study, for a prevalence
up to 33.3%, the NPV is over 90%. Colombia has recently completed the first nation-wide mul-
ticentric seroprevalence study of total (IgG/IgM) anti-SARS-CoV-2 antibodies, conducted
between October and November, 2020 [33]. Estimated seropositivity frequencies ranged
between 27% and 59% [33, 34], using the SARS-CoV-2 Total (COV2T) Advia Centaur–Sie-
mens chemiluminescent immunoassay [34]. Considering the result of seroprevalence in Cali,
which was 27% (CI 95%: 22–32%) [34], we estimate the negative predictive value of this test to
be currently close to 93%.
Decline of antibody titers and seropositivity has been reported for different tests, including
the Abbott IgG [30, 35–38]. In our study, sensitivity of the test in the subset of patients >60
days from symptom onset was 88%, indicating that IgG responses can be tracked in individuals
during the first two months. This coincides with previous reports of a median half-life of anti-
bodies detected by Abbott of 86 days [35], and a decay in seropositivity after 90 days reported
in a Brazilian population evaluated with this test [39]. These aspects should be considered
when analyzing and interpreting serosurveys conducted globally with the Abbott assay, since
the true cumulative number of SARS-CoV-2 infections may be underestimated. However,
knowledge of the test’s performance and antibody dynamics would help to account for these
aspects in estimation of seroprevalence [36, 40].
An important aspect of performance verification studies is the selection of the “reference
standard”. For antigen, as well as antibody-based diagnostic tools for COVID-19, the reference
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standard has been defined as RT-PCR by national and international guidelines [29, 41]. How-
ever, a number of RT-PCR gene targets, commercial (and in-house) kits and amplification
platforms are available for viral detection. Due to variability in the methodological conforma-
tion of these processes, these tools also differ in the amplification efficiencies and limits of
detection (eg. lower limit of detection -LOD- or lower limit of quantitation–LLOQ-) which, as
an example, can range from 3.8 to 23 copies/mL (LOD95) [42]. These differences introduce
limitations that need to be considered for generalizability of the results and contrasts with
other studies.
Ten of the 14 patients with discordant results were diagnosed by amplification of E and
RdRP targets, while the Abbott IgG tests detects antibodies against the viral nucleocapsid pro-
tein. Differences in the molecular targets could contribute to the observed discrepancies and
call for a more refined definition of what the reference standard for COVID-19 diagnostics is.
A limitation of our study was that separate groups of samples were used for the calculation
of sensitivity and specificity, the latter coming from patients without respiratory symptoms,
and lack of inclusion of asymptomatic patients which limits our ability to make inferences in
this important group. Plasma and serum samples were used for this study, as indicated by the
manufacturer. These samples are aligned with the acceptable characteristics of the WHO Tar-
get Product Profiles for antibody tests. However, samples that are the easier to collect (e.g.
blood spots) can be developed as innovations to facilitate sampling and accessibility of the
technology [28]. Presence of SARS-CoV-2 variants, and their potential effects on test perfor-
mance, was not assessed in this study. Despite this, the population enrolled for testing was rep-
resentative of the spectrum of patients and age groups seeking care in a reference facility in
Colombia, with a breadth of clinical presentations (from mild to severely ill). Results from this
study provide information on the specific use of this antibody test in the population for which
it is intended to be used and highlight some important limitations in the interpretation of
results based on the current reference standard definitions and duration of seropositivity.
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